Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Efficacy of Brodalumab in the Treatment of Immune-Related Adverse Events: A Pilot Study

NCT06673329 is registered in ClinicalTrials.gov with Brian Henick, MD as lead sponsor.

NCT NCT06673329
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06673329 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Efficacy of Brodalumab in the Treatment of Immune-Related Adverse Events: A Pilot Study
Lead sponsor
Brian Henick, MD
Phase
Phase 1
Overall status
Recruiting
Start date
March 11, 2025
Completion date
November 30, 2027
Enrollment
11 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

brain tumor, breast cancer, colon cancer, esophageal cancer, gynecologic cancer, head and neck cancer, kidney cancer, liver cancer, lung cancer, oral cancer, pancreatic cancer, prostate cancer, rectal cancer, skin cancer, solid tumor, stomach cancer, testicular cancer, thyroid cancer